This article is more than 5 years old. Information may no longer be current.

NICE recommends Ozurdex for noninfectious posterior uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The National Institute for Health and Care Excellence in the United Kingdom has issued a final appraisal determination recommending Ozurdex for the treatment of noninfectious posterior uveitis, according to an Allergan press release.

If confirmed as final guidance, the final appraisal determination would allow Ozurdex (dexamethasone 0.7 mg intravitreal implant) to be a fully funded treatment option for patients with noninfectious uveitis in the posterior segment. It is already funded for posterior segment uveitis in some parts of the U.K., the release said.

“The [final appraisal determination] recommendation by NICE is welcome news for patients. As final guidance, it would mean improved access to treatments, including Ozurdex and their availability in places where this was impossible before,” Jessica Hall, advocacy policy project officer for the Royal National Institute of Blind People, said in the release. “Given that the vision loss associated with uveitis is potentially avoidable, it is right that the NHS pays for treatments that NICE has shown are cost and clinically effective in this area.”